ASSIST Study: Investigation of a digital health solution providing real-time inhaler technique guidance

Not Applicable

• Conditions: Asthma; Respiratory

• Registration Number: ISRCTN14411274
• Lead Sponsor: niversity of Manchester

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-06-08
• Last Update Posted: 8 April 2024
• Study Completion: 2024-04-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 126

Inclusion Criteria

1. Provision of signed and dated informed consent
2. Willingness to comply with the study procedures and confirmed availability for the study duration
3. Aged =16 years
4. Self-reported asthma diagnosis and currently receiving treatment
5. Regularly prescribed one of the following brands of inhaler and has been using it for at least 1-month prior to enrolment:
5.1. Fostair pMDI (100 mcg Beclometasone/ 6 mcg Formoterol per dose; 200 mcg Beclometasone/ 6mcg Formoterol per dose); Chiesi Ltd
5.2. Clenil Modulite pMDI (50 mcg, 100 mcg, 200 mcg or 250 mcg Beclometasone per dose); Chiesi Ltd
5.3. Trimbow pMDI (87 mcg Beclometasone, 5 mcg Formoterol, 9 mcg Glycopyrronium per dose); Chiesi Ltd
5.4. Seretide Evohaler pMDI (50 mcg Fluticasone/Salmeterol 25 mcg per dose; 125 mcg Fluticasone/Salmeterol 25 mcg per dose; 250 mcg Fluticasone/ Salmeterol 25 mcg per dose); GSK UK Ltd
5.5. Flixotide Evohaler pMDI (50 mcg Fluticasone per dose; 125 mcg Fluticasone per dose; 250 mcg Fluticasone per dose); GSK UK Ltd
6. Access to a smartphone or tablet device and willingness to use it to regularly assess inhaler technique for the study duration

Exclusion Criteria

1. Using a spacer to assist with using their inhaler
2. Prescribed oral steroids for asthma in the preceding 1-month
3. Medication is not self-administered
4. Previous treatment for acute asthma in an IC

Study & Design

• Study Type: Interventional
• Study Design: Not specified